Lite Strategy (LITS) Net Shares Issued and Repurchased (2011 - 2025)
Lite Strategy (LITS) posted Net Shares Issued and Repurchased of $488065.0 for Q2 2025, up 109.0% on a QoQ basis from $233528.0 in Q3 2024, and down 99.83% year-over-year from $290.4 million in Q2 2024.
Analysis
Lite Strategy (LITS) Net Shares Issued and Repurchased (2011 - 2025) Analysis & Trends
Lite Strategy has reported Net Shares Issued and Repurchased for 13 years, with the latest figure at $488065.0 in Q2 2025.
- On a quarterly basis, Net Shares Issued and Repurchased fell 99.83% year-over-year to $488065.0 in Q2 2025; TTM through Jun 2025 was $488065.0, a 99.83% decrease from a year earlier, with the FY2025 full-year figure at $488065.0, down 99.83% from the prior year.
- Net Shares Issued and Repurchased was $488065.0 for Q2 2025 at Lite Strategy, up from $233528.0 in the prior quarter.
- The five-year high for Net Shares Issued and Repurchased was $7.1 billion in Q2 2022, with the low at $227037.0 in Q3 2023.
- Average Net Shares Issued and Repurchased over 5 years is $928.5 million, with a median of $2.9 million recorded in 2021.
- The sharpest annual moves came in 2022 and 2023: Net Shares Issued and Repurchased surged 114790.97% in 2022, then sank 99.99% in 2023.
- Over 5 years, Net Shares Issued and Repurchased stood at $5.1 million in 2021, then surged by 140944.74% to $7.1 billion in 2022, then plunged by 100.0% to $227037.0 in 2023, then climbed by 2.86% to $233528.0 in 2024, then soared by 109.0% to $488065.0 in 2025.
- The last three Net Shares Issued and Repurchased figures came in at $488065.0 (Q2 2025), $233528.0 (Q3 2024), and $290.4 million (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 488,065.00 |
| Sep 30, 2024 | 233,528.00 |
| Jun 30, 2024 | 290.44 Mn |
| Sep 30, 2023 | 227,037.00 |
| Jun 30, 2023 | 682,074.00 |
| Jun 30, 2022 | 7.12 Bn |
| Sep 30, 2021 | 5.05 Mn |
| Jun 30, 2021 | 6.20 Mn |
| Sep 30, 2018 | 2.02 Mn |
| Jun 30, 2018 | 2.77 Mn |
| Sep 30, 2017 | 1.59 Mn |
| Jun 30, 2017 | 1.71 Mn |
| Sep 30, 2016 | 1.49 Mn |
| Jun 30, 2016 | 1,712.00 |
| Sep 30, 2015 | 1.19 Mn |
| Jun 30, 2015 | 807,697.00 |
| Sep 30, 2014 | 483,241.00 |
| Jun 30, 2014 | 568,593.00 |
| Sep 30, 2013 | 325,355.00 |
| Jun 30, 2013 | 491,168.00 |